药学学报, 2019, 54(12): 2308-2315
引用本文:
李涛, 赵小亮, 聂颖兰, 焦玥, 刘洋, 张美玉, 李玉娟, 王志国, 王丹巧. CQ止痛复方中青藤碱和川芎嗪的脑通透性研究[J]. 药学学报, 2019, 54(12): 2308-2315.
LI Tao, ZHAO Xiao-liang, NIE Ying-lan, JIAO Yue, LIU Yang, ZHANG Mei-yu, LI Yu-juan, WANG Zhi-guo, WANG Dan-qiao. UHPLC quantification and brain permeability study of sinomenine and ligustrazine in CQM after single intravenous administration[J]. Acta Pharmaceutica Sinica, 2019, 54(12): 2308-2315.

CQ止痛复方中青藤碱和川芎嗪的脑通透性研究
李涛, 赵小亮, 聂颖兰, 焦玥, 刘洋, 张美玉, 李玉娟, 王志国, 王丹巧
中国中医科学院医学实验中心, 北京市中医药防治重大疾病基础研究重点实验室, 北京 100700
摘要:
建立给予CQ止痛复方(Chuanxiong Qingfengteng mixture,CQM)后大、小鼠血浆、脑组织及细胞液等生物样品中青藤碱和川芎嗪的UHPLC-UV定量分析方法,并研究这两种组分的脑通透性。分析方法经选择性、线性范围、准确度、精密度、稳定性等考察确证适合以上生物样品中青藤碱和川芎嗪的测定。大鼠和小鼠静脉注射CQM,5 min~2 h在脑脊液和脑组织均能检测到青藤碱和川芎嗪,且脑组织与脑脊液的浓度具有强烈的相关性(Pearson's R>0.86,P<0.001);其中,川芎嗪的脑组织/血浆分配系数高于青藤碱。血浆游离分数青藤碱为78.92%,川芎嗪为34.07%,且在各自浓度范围内血浆蛋白结合率无明显依赖性。Caco-2细胞孵育CQM,青藤碱和川芎嗪在细胞单层膜上表观渗透系数(Papp)分别为1.30和3.64×10-6 cm·s-1,属中通透性和高通透性化合物;联用P-糖蛋白(P-gp)抑制剂后,各组分Papp均未增加。上述结果表明CQM各组分能快速通过血脑屏障;川芎嗪的脑通透性高于青藤碱;各组分的跨膜转运可能不受P-gp等外排转运体的影响。本研究所有动物实验过程和动物关怀均遵守中华人民共和国《实验动物管理条例》,并得到中国中医科学院医学实验中心伦理委员会的批准。
关键词:    青藤碱      川芎嗪      脑通透性      血脑屏障      转运体     
UHPLC quantification and brain permeability study of sinomenine and ligustrazine in CQM after single intravenous administration
LI Tao, ZHAO Xiao-liang, NIE Ying-lan, JIAO Yue, LIU Yang, ZHANG Mei-yu, LI Yu-juan, WANG Zhi-guo, WANG Dan-qiao
Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment of Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China
Abstract:
Chuanxiong Qingfengteng mixture (CQM) is an analgesic developed based on clinical evidence and traditional Chinese medicine theory, which majorly consists of Ligusticum chuanxiong and Sinomenium acutum extracts. The current study aims to establish an UHPLC-UV method for the quantification of sinomenine and ligustrazine after CQM administration to rats, mice and cells, and to study the brain permeability of sinomenine and ligustrazine. The selectivity, linearity, accuracy, precision and stability of the established method demonstrated that it was suitable for the determination of sinomenine and ligustrazine in biological samples such as plasma, brain tissue and cellular fluid. After CQM was intravenously administered to rats and mice, both sinomenine and ligustrazine were detected in the brain from 5 min-2 h. The CSF/plasma partition coefficients (Kp, C/P) of each component were higher than those of brain tissue/plasma partition coefficient (Kp, B/P), the Kp, C/P and Kp, B/P of ligustrazine were higher than those of sinomenine. The concentrations between CSF and brain tissue were strongly correlated (Pearson's R>0.86, P<0.001). The unbound fraction in plasma of sinomenine and ligustrazine was 78.92% and 34.07%, respectively. The plasma protein binding rates displayed concentration-independent behavior within their respective in vivo concentration ranges. After CQM co-cultured with Caco-2 cell monolayers, the apparent permeability coefficient (Papp) of sinomenine and ligustrazine were 1.30×10-6 and 3.64×10-6 cm·s-1, respectively, following into the range of the intermediate and high permeability compounds. The efflux ratio (Papp(basolateral→apical)/Papp(apical→basolateral)) of sinomenine and ligustrazine were 0.67 and 0.85, respectively. When combined with P-glycoprotein inhibitor, the Papp of each component did not increase. In conclusion, the UHPLC-UV assay was successfully applied for the brain permeability study of CQM, the components of CQM can be quickly distributed to cerebrospinal fluid and pass through the blood-brain barrier. The brain permeability of ligustrazine is higher than that of sinomenine. The transmembrane transport of sinomenine and ligustrazine may not be affected by efflux transporters. All animal care and use complied with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of the People's Republic of China. All animal studies were implemented according to protocols, which were reviewed and approved by the Institutional Animal Care and Use Committee at Experimental Research Center, China Academy of Chinese Medical Sciences.
Key words:    sinomenine    ligustrazine    brain permeability    blood-brain barrier    drug transporter   
收稿日期: 2019-06-26
DOI: 10.16438/j.0513-4870.2019-0515
基金项目: 国家自然科学基金资助项目(81503278);中国中医科学院自主业务选题资助项目(ZZ2016001,ZZ2014001).
通讯作者: 王丹巧,Tel:86-10-64089529,Fax:86-10-64020477,E-mail:dq_wang96@163.com
Email: dq_wang96@163.com
相关功能
PDF(1734KB) Free
打印本文
0
作者相关文章
李涛  在本刊中的所有文章
赵小亮  在本刊中的所有文章
聂颖兰  在本刊中的所有文章
焦玥  在本刊中的所有文章
刘洋  在本刊中的所有文章
张美玉  在本刊中的所有文章
李玉娟  在本刊中的所有文章
王志国  在本刊中的所有文章
王丹巧  在本刊中的所有文章

参考文献:
[1] Wang DQ, Li LD, Zhao XL, et al. CQM, a compound drug composition composed of Ligusticum chuanxiong and Sinomenium acutum extracts:CN, 103083401A[P]. 2013-05-08.
[2] Li P, Zhang MY, Wang DQ, et al. Effects of sinomenine on analgesia and exciting amino acid neurotransmitters in brain of SSNI rat model[J]. Chin Pharmacol Bull (中国药理学通报), 2012, 28:1365-1369.
[3] Wang Y, Wang DQ, Cui Y, et al. Analgesic effect of CQM on prosopalgia model rats and its impact on exciting amino acid neurotransmitters[J]. China J Chin Mater Med (中国中药杂志), 2013, 38:3554-3559.
[4] Gao TL, Shi TS, Wiesenfeld-Hallin Z, et al. Sinomenine facilitates the efficacy of gabapentin or ligustrazine hydrochloride in animal models of neuropathic pain[J]. Eur J Pharmacol, 2019, 854:101-108.
[5] Zhao XL, Liu Y, Wang Y, et al. Effects of sinomenine on analgesia and contents of substance P in central nervous system of incisional pain rat model[J]. Label Immunoass Clin Med (标记免疫分析与临床), 2013, 20:422-426.
[6] Zhang Y, Wang ZG, Ouyang JF, et al. Analgesic effect and mechanism of CQ compound on rats model with tibia metastatic cancer pain[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2017, 23:119-124.
[7] Jiang YM, Sun DD, Wang ZG, et al. Analgesic effect and central mechanisms of CQ prescription on cancer invasion induced mirror image pain in model mice[J]. China J Chin Mater Med (中国中药杂志), 2017, 42:739-745.
[8] Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. Transporters at CNS barrier sites:obstacles or opportunities for drug delivery?[J]. Curr Pharm Des. 2014, 20:1422-1449.
[9] Guo B, Li C, Wang GJ, et al. Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma[J]. Rapid Commun Mass Spectrom, 2006, 20:39-47.
[10] Yang XW, Yang XD, Wang Y, et al. Establishment of Caco-2 cell monolayer model and standard operation procedure for assessing intestinal absorption of chemical components of traditional Chinese medicine[J]. J Chin Integr Med (中西医结合学报), 2007, 5:634-641.
[11] Li L, Zhao Y, Du F, et al. Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves[J]. Curr Drug Metab, 2012, 13:494-509.
[12] Chinese Pharmacopoeia Commission. Guiding Principles for Quantitative Analysis of Biological Samples[S]//Chinese Pharmacopoeia (中国药典),2015ed. Beijing:China Medicine Science and Technology Press, 2015.
[13] Liu ZQ, Chan K, Zhou H, et al. The pharmacokinetics and tissue distribution of sinomenine in rats and its protein binding ability in vitro[J]. Life Sci, 2005, 77:3197-3209.
[14] Long LH, Wu PF, Chen XL, et al. HPLC and LC-MS analysis of sinomenine and its application in pharmacokinetic studies in rats[J]. Acta Pharmacol Sin, 2010, 31:1508-1514.
[15] Zhao XL, Li T, Liu Y, et al. Pharmacokinetic analysis of sinomenine based on automatic blood sampling system and HPLC-QQQ-MS[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2015, 21:66-70.
[16] Liang CC, Hong CY, Chen CF, et al. Measurement and pharmacokinetic study of tetramethylpyrazine in rat blood and its regional brain tissue by high-performance liquid chromatography[J]. J Chromatogr B:Biomed Sci Appl, 1999, 724:303-309.
[17] Xu HY, Tang Z, Wang Q. Brain and blood pharmacokinetics of tetramethylpyrazine hydrochloride after intraperitoneal administration in rats by microdialysis[J]. Chin J Clin Pharm (中国临床药学杂志), 2013, 22:206-211.
[18] Pardridge WM. CSF, blood-brain barrier, and brain drug delivery[J]. Expert Opin Drug Deliv, 2016, 13:963-975.
[19] Li Y, Duan Z, Tian Y, et al. A novel perspective and approach to intestinal octreotide absorption:sinomenine-mediated reversible tight junction opening and its molecular mechanism[J]. Int J Mol Sci, 2013, 14:12873-12892.
[20] Wang Y. Effect of Ligustrazine on the Blood-brain Barrier Model Permeability in vitro and Part of the Mechanism (川芎嗪对体外血脑屏障模型通透性的影响及部分作用机制)[D]. Heifei:Anhui University of Chinese Medicine, 2013.
[21] Chen Y, Zhang L, Lu X, et al. Sinomenine reverses multidrug resistance in bladder cancer cells via P-glycoprotein-dependent and independent manners[J]. Pharmazie, 2014, 69:48-54.
[22] Wang XB, Wang SS, Zhang QF, et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells[J]. Oncol Rep, 2010, 23:211-215.
[23] Liu XL, Tang J, Song J, et al. The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats[J]. Acta Pharm Sin (药学学报), 2006, 41:882-887.
[24] Ge JD, Chen M, Song BW. Absorption mechanism of tetramethylpyrazine hydrochloride across PAMPA and MDCK monolayers[J]. J Zhejiang Univ Technol (浙江工业大学学报), 2010, 38:616-619.
[25] Li XY. Study on Absorption Mechanism and Pharmacokinetics of Sinomenine (青藤碱的肠吸收特性及药动学研究)[D]. Shenyang:China Medical University, 2010.